Moxibustion for Mild and Moderate Ulcerative Colitis

The Mechanism of Moxibustion in Treating Ulcerative Colitis Based on Metabonomics

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02084186

Enrollment

Registered

2014-03-11

Start date

2014-03-31

Completion date

2015-12-31

Last updated

2016-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

The purpose of this study is to determine whether moxibustion is effective to mild and moderate ulcerative colitis and the effect of moxibustion on metabolism.

Interventions

OTHERherb-partitioned moxibustion

Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.

OTHERbran-partitioned moxibustion

Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Meet the diagnosis of UC * Mayo ≤10 * Patients should have never received any pharmacological therapy or if they are receiving aminosalicylates and/or prednisolone (the dosage has been taken at least 4 weeks, and should be kept the same as before throughout the trial) * Patients should have never received antibiotic, biologicals, probiotics, acetaminophen, acetamide and contraceptive. * A written informed consent

Exclusion criteria

* Patients with cardiac, encephalic, hepatic, nephric, hematopoietic system, psychotic or any other serious diseases * Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
disease activity index (DAI)	3 months	Using Mayo subscore

Secondary

Measure	Time frame	Description
Inflammatory Bowel Disease Questionnaire (IBDQ)	3 months	—
symptom score	3 months	—
histomorphology observation of intestinal mucosa	3 months	Using the Geboes histology score
metabolic profile of intestinal mucosa, urine, plasma and serum	3 months	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026